Suzhou Alphamab Co., Ltd.

This Phase 3 trial tests a new drug called KN057, given as a weekly injection, to prevent bleeding in people with hemophilia A or B who do not have inhibitors. The study includes 125 males aged 12 to 70 with severe or moderately severe hemophilia. Participants are split into grou…

This study tests a weekly injection called KN057 to see if it can prevent bleeding episodes in people with hemophilia A or B who have developed inhibitors (antibodies that block standard treatment). About 53 male participants aged 12 to 70 will be randomly assigned to receive KN0…

This study tests a new drug called KN060, given as a single intravenous dose, to prevent blood clots in people having total knee replacement surgery. It compares KN060 to the standard treatment enoxaparin, which requires daily injections. The trial involves 241 adults and is curr…